AstraZeneca-Oxford Covid-19 vaccine is a recombinant adenovirus vaccine that uses a live pathogen.
The Oxford–AstraZeneca vaccine is made from a cold-causing adenovirus that was isolated from the stool of chimpanzees and modified so that it no longer replicates in cells. When injected, the vaccine instructs human cells to produce the SARS-CoV-2 spike protein — the immune system’s main target in coronavirusesne drawback of recombinant adenoviral vector vaccines is that booster shots may be required over time.
the only commercially available adenovirus-based vaccine of this type is the rabies vaccine.
There are controversies on dosing discrepancies in some study groups, and a move by the U.S. Food and Drug Administration (FDA) to pause the trial because of unexplained illness.
According to the trial report, the AstraZeneca-Oxford vaccine is about 70% effective on average. However, this average was calculated after a 62% effective rate was observed in people who received the full vaccine dose compared with 90% effective in those who received the half dose. Additional reviews are ongoing, and it remains unclear at this time why a half-dose of vaccine might have worked better than a full second dose.
The company said trials are still underway around the world, but that—pending regulatory approval—as many as 3 billion doses could be available in 2021.8 A number of countries have already ordered doses of the vaccine.
Once available, the vaccine may be able to be more easily distributed than some other options.
According to the trial report, the AstraZeneca-Oxford vaccine is about 70% effective on average. However, this average was calculated after a 62% effective rate was observed in people who received the full vaccine dose compared with 90% effective in those who received the half dose. Additional reviews are ongoing,
References:
https://www.verywellhealth.com/astrazeneca-oxford-covid-19-vaccine-5093148..
https://www.nature.com/articles/d41586-020-03326-w
Actually, the method used by AstraZeneca-Oxford for their Covid-19 vaccine is a clever one indeed but may be difficult in meeting the goal of pro-phylactic or post-phylactic immunotherapic efficacy. It is based on a technique that was developed and has been in use before the insight for mRNA based vaccines breasted the success tape of novel entry into vaccine science and related discoveries..
Your views, please
- Badges
- Science topic
- Similar topics
- Clinical Pharmacology
- Dosing